Open AccessReduction in Peripheral CD19+CD24hCD27+ B Cell Frequency Predicts Favourable Clinical Course in XELOX-Treated Patients with Advanced Gastric Cancer
Author(s) -
Wei Li,
Dongli Song,
Hong Li,
Li Liang,
Na Zhao,
Tianshu Liu
Publication year - 2017
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000475435
Subject(s) - medicine , capecitabine , oxaliplatin , gastroenterology , cd19 , cancer , chemotherapy , oncology , adverse effect , clinical endpoint , clinical trial , colorectal cancer , peripheral blood
Accumulating evidence suggests that regulatory B cells (Bregs) play an important role in modulating the immune response to tumours. Our previous study indicated that a small percentage of peripheral CD19+CD24hCD27+ Breg cells slowed gastric cancer progression in XELOX-treated patients. Here, we further investigated the relationship between dynamic changes in circulating Breg cells and the clinical course in XELOX-treated gastric cancer patients.